Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies

被引：63
作者：
Jacob, Saiju [1 ]
Rajabally, Yusuf A. [1 ]
机构：
[1] Leicester Gen Hosp, Univ Hosp Leicester, Dept Neurol, Neuromuscular Clin, Leicester LE5 4PW, Leics, England
来源：
CURRENT NEUROPHARMACOLOGY | 2009年 / 7卷 / 04期
关键词：
Intravenous immunoglobulins; mechanisms of action; inflammatory neuropathy; Guillain Barre syndrome; Chronic inflammatory demyelinating polyneuropathy; multifocal motor neuropathy; MULTIFOCAL MOTOR NEUROPATHY; GUILLAIN-BARRE-SYNDROME; IMMUNE GLOBULIN THERAPY; IN-VITRO INHIBITION; GAMMA-GLOBULIN; DOUBLE-BLIND; ANTIINFLAMMATORY ACTIVITY; RECEPTOR ANTAGONIST; MYASTHENIA-GRAVIS; ANTIBODIES;
D O I：
10.2174/157015909790031166
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Intravenous immunoglobulins (IVIg) have been shown in a number of trials, to be an effective treatment for the three main types of inflammatory neuropathies: Guillain-Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is thought to exert its immunomodulatory effects by affecting several components of the immune system including B-cells, T-cells, macrophages, complement, cytokines and cellular adhesion molecules. This article reviews the published evidence and the principal postulated mechanisms of action of intravenous immunoglobulins with special emphasis on inflammatory neuropathies.
引用
收藏
页码：337 / 342
页数：6
相关论文
共 79 条
[1]  
AUKRUST P, 1994, BLOOD, V84, P2136
[2]   INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN PATIENTS WITH MOTOR-NEURON SYNDROMES ASSOCIATED WITH ANTI-GM1 ANTIBODIES - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
AZULAY, JP ;
BLIN, O ;
POUGET, J ;
BOUCRAUT, J ;
BILLETURC, F ;
CARLES, G ;
SERRATRICE, G .
NEUROLOGY, 1994, 44 (03) :429-432
[3]   Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis [J].
Basta, M ;
Illa, I ;
Dalakas, MC .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 71 (1-2) :227-229
[4]   F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins:: a novel effector function of immunoglobulins [J].
Basta, M ;
Van Goor, F ;
Luccioli, S ;
Billings, EM ;
Vortmeyer, AO ;
Baranyi, L ;
Szebeni, J ;
Alving, CR ;
Carroll, MC ;
Berkower, I ;
Stojilkovic, SS ;
Metcalfe, DD .
NATURE MEDICINE, 2003, 9 (04) :431-438
[5]   The efficacy of specific IVIG anti-idiotypic antibodies in anti phospholipid syndrome (APS): trophoblast invasiveness and APS animal model [J].
Blank, Mid ;
Anafi, Liat ;
Zandman-Goddard, Gisele ;
Krause, Ilan ;
Goldman, Shlomit ;
Shalev, Eliezer ;
Cervera, Ricard ;
Font, Josep ;
Fridkin, Mati ;
Thiesen, Hans-Jurgen ;
Shoenfeld, Yehuda .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (07) :857-865
[6]   Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1 [J].
Bouhlal, H ;
Hocini, H ;
Quillent-Grégoire, C ;
Donkova, V ;
Rose, S ;
Amara, A ;
Longhi, R ;
Haeffner-Cavaillon, N ;
Beretta, A ;
Kaveri, SV ;
Kazatchkine, MD .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7606-7611
[7]   The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy [J].
Chapel, HM ;
Spickett, GP ;
Ericson, D ;
Engl, W ;
Eibl, MM ;
Bjorkander, J .
JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (02) :94-100
[8]   CONSENSUS ON DIAGNOSIS AND MANAGEMENT OF PRIMARY ANTIBODY DEFICIENCIES [J].
CHAPEL, HM ;
COLE, P ;
GABRIEL, C ;
MILLA, P ;
MORGAN, G ;
SCADDING, G ;
WINFIELD, D ;
BRENNAN, V ;
CARNE, S ;
EWART, H ;
HORN, A ;
JARVIS, F ;
BROWN, D ;
HAENEY, M ;
LEVINSKY, R ;
THOMPSON, R ;
WEBSTER, D ;
WALLINGTON, T .
BRITISH MEDICAL JOURNAL, 1994, 308 (6928) :581-585
[9]  
CHAPEL HM, 1994, BRIT MED J, V308, P913
[10]   Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcγRII expression in patients with chronic inflammatory neuropathies [J].
Créange, A ;
Gregson, NA ;
Hughes, RAC .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 135 (1-2) :91-95
12345678